14 / 04 / 2024
New WHO data on co-administration of treatment for drug-resistant tuberculosis and hepatitis C

The expert evidence indicated that co-administering MDR-TB and HCV treatments, as compared to delaying HCV treatment while treating MDR-TB alone, may yield several benefits.

These benefits include an increase in MDR-TB treatment success rates, fewer cases of MDR-TB treatment failure, reduced instances of patients lost to follow-up, and a slight decrease in mortality rates. 

This is stated in rapid communication of the World Health Organization (WHO), published in April 2024. 

This rapid communication aims to inform national TB programmes, technical partners, and other stakeholders about the key implications for the co-administration of treatment for drug-resistant tuberculosis and hepatitis C, facilitating seamless integration and planning at the country level.

Co-administration of treatment for drug-resistant tuberculosis and hepatitis C: rapid communicationWorld Health Organization, 2024 Mar (EN)